Sorafenib Versus Other Targeted Agents in Metastatic Renal Cell Carcinoma
Posted: Wednesday, January 30, 2019
Ming Xia, MD, of the Capital Medical University, Beijing, China, and colleague Hai-Tao Wang, MD, PhD, of the Tianjin Medical University Cancer Institute and Hospital, suggest that targeted agents other than sorafenib may yield better response rates and progression-free survival in patients with metastatic renal cell carcinoma than sorafenib alone. Their study, which was a meta-analysis of sorafenib’s efficacy, was published in the journal Medicine. The authors indicated that further research is necessary to determine whether sorafenib should be replaced as the primary option for future treatment.
The study’s two researchers went through databases through September 2017. After starting with 364 studies, they narrowed down their analysis to a total of 5 randomized controlled trials, which were related to the addition of sorafenib to chemotherapy. The researchers then assessed the primary outcomes of objective response rate, progression-free survival, overall survival, and adverse events.
“The group of [adverse events] showed significantly improved [progression-free survival] (odds ratio [OR] = 0.78, as well with the [objective response rate] (OR = 1.89),” they reported. “However, there was no significant difference in [overall survival] (OR = 0.97).” They found an association between progression-free survival and factors including demographic and clinical characteristics and the total of metastases. Their analysis also found that sorafenib may improve outcomes for intermediate-risk patients and additionally for patients who had liver metastases and bone metastases.
Disclosure: The authors reported no conflicts of interest.